GEA
CRDF icon

Glen Eagle Advisors’s Cardiff Oncology CRDF Stock Holding History

Glen Eagle Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$333 – 1065
2021
Q2 		$333 Hold
50
– – ﹤0.01% 1011
2021
Q1 		$463 Hold
50
– – ﹤0.01% 969
2020
Q4 		$900 Buy
50
+45
+900% +$791 ﹤0.01% 915
2020
Q3 		$71 Hold
5
– – ﹤0.01% 904
2020
Q2 		$25 Buy
+5
New +$10 ﹤0.01% 897

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Eagle Advisors's CRDF Position: Q3 2021 in Review

Glen Eagle Advisors sold out of Cardiff Oncology (CRDF) in Q3 2021, closing a stake of 50 shares — an estimated $333 sold.

Glen Eagle Advisors first reported a position in CRDF in Q2 2020 and held it in 5 quarters. The position peaked at $900 in Q4 2020. 94 funds tracked by Wall St. Rank hold CRDF as of Q3 2021.

  • Glen Eagle Advisors reported no remaining Cardiff Oncology position as of Q3 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 50 Cardiff Oncology shares in Q3 2021, an estimated $333.
  • Glen Eagle Advisors first reported a position in Cardiff Oncology in Q2 2020 and held it in 5 quarters.
  • Glen Eagle Advisors's Cardiff Oncology position peaked at $900 in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2021.

Based on Glen Eagle Advisors's 13F filing for Q3 2021, filed 13 Aug 2024.